The role of mesenchymal stem cell (MSC)-derived exosomes is gaining increasing attention in facilitating cell-to-cell communication, and playing a crucial role in tissue regeneration, inflammation modulation, immune regulation, and drug delivery. They are considered as a promising cell-free therapy for various diseases.
MSC-derived exosomes are less likely to induce tumorigenicity or immune rejection compared to MSCs themselves, and are easier to be produced and preserved than stem cells. Moreover, these exosomes can be engineered to target specific cells or tissues, enhancing their therapeutic efficacy. Overall, MSC-derived exosomes are a promising cell-free therapy with a wide range of potential applications in regenerative medicine and beyond.
AcceGen provides high-quality Human MSC-Derived Exosomes, supporting studies on the therapeutic applications of MSC-derived exosomes in wound healing, cardiovascular disease, Neurodegenerative disease, cancer, and other diseases such as osteoarthritis, graft-versus-host disease, and type 1 diabetes.
